Skip to main content
SpringerLink
Log in

Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major

  • Case Report
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Cardiac complications caused by iron deposition are major causes of death in patients with β-thalassemia major. Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX). Furthermore, combined therapy with L1 and DFX produced an additive or synergistic iron chelating effect. We report the successful treatment of severe heart failure in two patients with β-thalassemia major with the combined therapy. Magnetic resonance images showed a marked recovery of signal intensity in the heart, indicating a significant reduction of iron load in the heart. No significant adverse effects were noted. Therefore, combined therapy with L1 and DFX should be considered in patients with β-thalassemia major and cardiac complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1A, B

Similar content being viewed by others

References

  1. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ (2002) Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 360:516–520

    Article  CAS  PubMed  Google Scholar 

  2. Wonke B, Wright C, Hoffbrand AV (1998) Combined therapy with deferiprone and desferrioxamine. Br J Haematol 103:361–364

    Article  CAS  PubMed  Google Scholar 

  3. Giardina PJ, Grady RW (2001) Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 38:360–366

    Article  CAS  PubMed  Google Scholar 

  4. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C (2001) Exploring the “iron shuttle” hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 138:130–138

    Article  CAS  PubMed  Google Scholar 

  5. Hershko C, Link G, Konijn AM, Huerta M, Rosenmann E, Reinus C (2002) The iron-loaded gerbil model revisited: effects of deferoxamine and deferiprone treatment. J Lab Clin Med 139:50–58

    Article  CAS  PubMed  Google Scholar 

  6. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khoriaty AI, Taher A (2003) Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 121:187–189

    CAS  PubMed  Google Scholar 

  7. Jessup M, Manno CS (1998) Diagnosis and management of iron-induced heart disease in Cooley’s anemia. Ann N Y Acad Sci 850:242–250

    CAS  PubMed  Google Scholar 

  8. Modell B, Khan M, Darlison M (2000) Survival in beta thalassemia major in the United Kingdom: data from the UK Thalassemia Register. Lancet 355:2051–2052

    Article  CAS  PubMed  Google Scholar 

  9. Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M (1993) Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major. Chest 103:1276-1278

    CAS  PubMed  Google Scholar 

  10. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ (2001) Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 22:2171–2179

    Article  CAS  PubMed  Google Scholar 

  11. Richardson DR (2002) Deferiprone: greater efficacy at depleting myocardial than hepatic iron? Lancet 360:501–502

    Article  PubMed  Google Scholar 

  12. Piga A, Gaglioti C, Fogliacco E, Tricta F (2003) Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 88:489–496

    CAS  PubMed  Google Scholar 

  13. Hoffbrand V (2001) Iron chelation: 2 better than 1? Blood 97:586

    Google Scholar 

  14. Mavrogeni SI, Maris T, Gouliamos A, Vlahos L, Kremastinos DT (1998) Myocardial iron deposition in beta-thalassemia studies by magnetic resonance imaging. Int J Card Imaging 14:117–122

    Article  CAS  PubMed  Google Scholar 

  15. Olivieri NF, Brittenham BM, McLaren CE, Templeton DM, Cameron RG, McClelland RA, Burt AD, Fleming KA (1998) Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 339:417–423

    CAS  PubMed  Google Scholar 

  16. Tondury P, Zimmermann A, Nielsen P, Hirt A (1998) Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patient. Br J Haematol 101:413–415

    Article  CAS  PubMed  Google Scholar 

  17. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini MR, Schwartz E, Cohen AR (2002) Lack of progressive hepatic fibrosis during long term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 100:1566–1569

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, China Medical University Hospital, 2 Yuh-Der Road, North District, 404, Taichung, Taiwan

    K. H. Wu, J. S. Chang, C. H. Tsai & C. T. Peng

Authors
  1. K. H. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. S. Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. H. Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. T. Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. T. Peng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, K.H., Chang, J.S., Tsai, C.H. et al. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with β-thalassemia major. Ann Hematol 83, 471–473 (2004). https://doi.org/10.1007/s00277-003-0820-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-003-0820-0

Keywords

Search

Navigation